Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Visit NurExone Biologic Inc.

NurExone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons.



Bullboard - Investor Discussion Forum NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

Healthcare Biotechnology
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following... see more

Bullboard (TSXV:NRX)

View:
Prev 1 2 3 4
Post by RealREIT$on Oct 05, 2023 11:09am

NurExone May Hold The Key To Potential Breakthrough In Acute

An estimated 250,000-500,000 people experience a Spinal Cord Injury (SCI) annually, with roughly 17,000 new cases in the US and 27,000 in Europe each year, leaving many of those people permanently ...more  
155
Post by RealREIT$on Oct 05, 2023 11:07am

NurExone May Hold The Key To Potential Breakthrough In Acute

Get to Know ExoTherapy and ExoPTEN One of the key assets of NurExone's technology is its drug delivery system, branded ExoTherapy. ExoTherapy is a play on the combination of exosomes with ...more  
86
Post by RealREIT$on Oct 05, 2023 11:06am

NurExone May Hold The Key To Potential Breakthrough In Acute

https://us11.campaign-archive.com/?u=3204f2d2592a7d2ac80467b2f&id=39bb6d2c60
82
Post by RealREIT$on Sep 13, 2023 12:44pm

NurExone Moves Forward Towards Human Clinical Trials

https://www.globenewswire.com/news-release/2023/09/13/2742459/0/en/NurExone-Moves-Forward-Towards-Human-Clinical-Trials-Completes-Pre-IND-Meeting-with-the-FDA-for-Proprietary-ExoPTEN-Drug.html
91
Post by Betteryear2on Jun 22, 2023 3:19pm

Regeneration & Reinnervation of Spinal Cord in Rats Treated

TORONTO and TEL AVIV, Israel, June 22, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX) (FSE: J90) (NRX.V), is pleased to report positive ...more  
161
Post by ThesisCapitalon Nov 30, 2022 10:28pm

NurExone: Loading Exosomes with Therapeutic Molecules

NurExone reported today results of a pre-clinical loading efficiency study that was completed by the Company showing that its innovative and proprietary loading technology has the potential to serve ...more  
175
Post by dkeller85on Mar 20, 2022 6:49am

Progress Update on RTO with Nurexone Biologic

Hot off the press: Calgary, Alberta--(Newsfile Corp. - March 15, 2022) - EnerSpar Corp. (TSXV: ENER) (FSE: 5E0) ("EnerSpar" or the "Company") is pleased to announce it ...more  
238
Prev 1 2 3 4
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.NRX

Visit Facebook Visit X Visit Linked In Visit Youtube



PRESENTATION TECHNOLOGY - EXOSOMES TECHNOLOGY - EXOTHERAPY MANAGEMENT ANALYST REPORT LEARN ABOUT ODD

Investor Presentation

View the Presentation

Investment Opportunity

NurExone operates according to two business lines – Development of a first exosome-based therapy for acute Spinal Cord Injuries (SCI).

In parallel, the company is monetizing its proprietary ExoTherapy platform through licensing to the global biopharmaceutical industry to deliver therapies for other diseases and indications.

The company’s first product, ExoPTEN, for acute spinal cord injury, has been granted Orphan Drug Designation by the FDA.



Why NurExone??

The Ultimate Drug Delivery System

The Beginning of NurExone

Facebook

Contact Us

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com

Dr. Eva Reuter Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu